Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 567-567 ◽

Cited By ~ 3

Author(s):

Klazien Matter-Walstra ◽

Matthias Schwenkglenks ◽

Peter Brauchli ◽

Dirk Klingbiel ◽

Konstantin J. Dedes

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Estrogen Receptor Positive ◽

A cost-effectiveness analysis of Herceptin® (trastuzumab) in combination with Paclitaxel as a first line treatment for HER2 positive (3+) Metastatic Breast Cancer (MBC) patients in the UK

European Journal of Cancer ◽

10.1016/s0959-8049(01)80043-5 ◽

2001 ◽

Vol 37 ◽

pp. 4 ◽

Cited By ~ 1

Author(s):

A. Ratcliffe ◽

C. Poole ◽

D. Miles

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Effectiveness Analysis ◽

The Uk ◽

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET+LAP) versus anastrozole plus trastuzumab (ANA+TZ) as first-line treatment for postmenopausal women with HER2+ and HR+ metastatic breast cancer (MBC) from the U.K. National Health Service (NHS) perspective.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1035 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1035-1035 ◽

Cited By ~ 1

Author(s):

V. Hastings ◽

T. E. Delea ◽

M. Amonkar ◽

K. Lykopoulos ◽

J. Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

National Health Service ◽

Indirect Comparison ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

The Cost ◽

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

European Journal of Cancer Care ◽

10.1111/ecc.12733 ◽

2017 ◽

Vol 26 (6) ◽

pp. e12733 ◽

Cited By ~ 10

Author(s):

H. Ding ◽

L. Fang ◽

W. Xin ◽

Y. Tong ◽

Q. Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Abstract 891: Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2- metastatic breast cancer in postmenopausal women in the United States

10.1158/1538-7445.am2021-891 ◽

2021 ◽

Author(s):

Prajakta P. Masurkar ◽

Haluk Damgacioglu ◽

Ashish Deshmukh ◽

Meghana Trivedi

Keyword(s):

Breast Cancer ◽

United States ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Metastatic Breast ◽

The United States ◽

Line Treatment ◽

First Line ◽

A First Cost-Effectiveness Analysis Based on Real Life Clinical Outcomes of Bevacizumab+ Paclitaxel Compared to Paclitaxel Among French Patients with HER2- Metastatic Breast Cancer in First Line of Treatment

Value in Health ◽

10.1016/j.jval.2016.09.2232 ◽

2016 ◽

Vol 19 (7) ◽

pp. A737

Author(s):

A Petitjean ◽

S Roze ◽

B Tehard

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Clinical Outcomes ◽

Real Life ◽

Metastatic Breast ◽

First Line ◽

Effectiveness Analysis

RE: “Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer,” by Ding H., et al.

European Journal of Cancer Care ◽

10.1111/ecc.12834 ◽

2018 ◽

Vol 27 (2) ◽

pp. e12834

Author(s):

Claire Telford

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China

Annals of Palliative Medicine ◽

10.21037/apm-21-2412 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

Hao Wang ◽

Ye Wang ◽

Ruixue Gong ◽

Yuyu Geng ◽

Li Li

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.6060 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 6060-6060 ◽

Cited By ~ 4

Author(s):

A. J. Montero ◽

S. Gluck ◽

G. d. L. Lopes

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

The Cost ◽